Scientists are reporting progress on a blood test to detect many types of cancer at an early stage, including some of the most deadly ones that lack screening tools now.
Many groups are working on liquid biopsy tests, which look for DNA and other things that tumors shed into blood, to try to find cancer before it spreads, when chances of cure are best.
In a study Thursday in the journal Science, Johns Hopkins University scientists looked to see how well their experimental test detected cancer in people already known to have the disease.
The blood tests found about 70 percent of eight common types of cancer in the 1,005 patients. The rates varied depending on the type — lower for breast tumors but high for ovarian, liver and pancreatic ones.
In many cases, the test narrowed the possible origin of the cancer to one or two places, such as colon or lung, important for limiting how much follow-up testing a patient might need. It gave only seven false alarms when tried on 812 others without cancer.
The test is nowhere near ready for use yet; it needs to be validated in a larger study already underway in a general population, rather than cancer patients, to see if it truly works and helps save lives — the best measure of a screening test’s value.
‘‘We’re very, very excited and see this as a first step,’’ said Nickolas Papadopoulos, one of the Hopkins study leaders. ‘‘But we don’t want people calling up’’ and asking for the test now, because it’s not available, he said.
Some independent experts saw great promise.
‘‘It’s such a good first set of results’’ that it gives hope this approach will pan out, said Dr. Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center who consults for a gene testing company.
‘‘Anything close to 50 percent or 40 percent detection is pretty exciting stuff,’’ and this one did better than that, he said.
Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, was encouraged that the test did well on cancers that lack screening tests now. If a blood test could find 98 percent of ovarian cancers at an early stage, as these early results suggest, ‘‘that would be a significant advance,’’ he said.
But he cautioned: ‘‘We have a long way to go to demonstrate its effectiveness as a screening test.’’